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The prostaglandins constitute a series of cyclic, 
oxygenated, 20-carbon fatty acids synthesized 
from the essential fatty acids and having a broad 
spectrum of biologic activity. The molecular skele-
ton common to all prostaglandins consists of a 
cyclopentane ring with two carbon side chains 
(Fig. 1). The prostaglandins are named by letter 
(A,B,C,D,E,F,G,H) according to substitutions 
made on the cyclopentane ring and, in the case of 
prostaglandin G, on carbon 15. Different numerical 
subscripts added to the letters designate the degree 
of unsaturation in the carbon side chains. The 
Greek letter a or {3, which sometimes follows the 
letter and number (for example, prostaglandin 
F 20), indicates the spatial orientation of the substi-
tutions on the cyclopentane ring (Fig. 2). Prosta-
glandins G and H represent two endoperoxide 
intermediates, recently described by Hamberg, 
Svensson, Wakabayashi, and Samuelsson (1], 
which are synthesized from arachidonic acid, the 
essential fatty acid precursor of prostaglandins E2 
and F 2a (PGE2, PGF20). They have a short half-life 
of approximately 5 min and are intriguing because 
their biologic activity is 10- to 40-fold greater than 
that of PGE2 (Fig. 3). 
RECOVERY OF PROSTAGLANDINS IN CUTANEOUS 
INFLAMMATION 
In 1970, Greaves and S0ndergaard [2] were the 
first investigators to demonstrate prostaglandin-
like activity in perfusates from human skin that 
had been irradiated .with ultraviolet light 24 to 48 
hr earlier. Mathur and Gandhi (3] demonstrated 
an increase in the prostaglandin content of human 
skin after exposure to ultraviolet light. The activity 
on purification by thin-layer chromatography was 
almost entirely recovered from the region of the E 
prostaglandins. Arturson, Hamberg, and Jonsson 
[4] recovered prostaglandins from human burn 
blister fluid using a smooth muscle bioassay sys-
tem in conjunction with thin-layer chromatogra-
phy. They demonstrated that the contracting ac-
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tivity of the smooth muscle was due to a combina-
tion of PGE2 and PGF 20. Goldyne, Winkelmann, 
and Ryan (5], using a radioimmunoassay specific 
for prostaglandins, found prostaglandin activity in 
human blister fluid induced by the vesicant can-
tharidin. More recently, S0ndergaard, Greaves, 
and J0rgensen [6] recovered a mixture of prosta-
glandins E and F in human primary irritant 
dermatitis induced by benzalkonium chloride. 
Thus, both physically and chemically induced 
cutaneous inflammation can be associated with 
prostaglandin activity. 
Prostaglandins also have been identified in in-
flammatory cutaneous lesions induced by immu-
nologic stimuli. In 1971, Greaves, S0ndergaard, 
and McDonald-Gibson [7] found prostaglandin 
activity in the dermal perfusates from 35 of 45 
patients with contact dermatitis of 48 hr duration. 
This activity was due to both E and F prostagland-
ins. Goldyne et al [5] found prostaglandin activity 
in the blister fluid from patients with bullous 
contact dermatitis. Prelimina~y studies also dem-
onstrated prostaglandin activity in blister fluid 
from patients with bullous pemphigoid and pem-
phigus vulgaris (Goldyne ME, Jordon RE, Winkel-
mann RK: Unpublished data).· Experimental evi-
dence, therefore, suggests that prostaglandins are a 
common denominator in cutaneous inflammation 
whether the inflammation results from toxic or 
immunologic stimuli (Tab. 1). 
PROSTAGLANDIN ACTIVITY AND THE EVOLUTION 
OF INFLAMMATION 
Clarifying the relationship of prostaglandins to 
cutaneous inflammation requires a correlation of 
the appearance of prostaglandin activity with the 
clinical evolution of the inflammatory response. In 
rats, prostaglandin activity appears in a sequential 
relationship to other mediators in acute inflamma-
tion. Studies by DiRosa, Giroud, and Willoughby 
[8] and by Willis [9] revealed three phases of 
mediator response to an intradermal injection of 
the irritant carrageenan. The first phase involved 
the release of histamine; the second phase was 
associated with kinin activity; and the third phase 
was associated with prostaglandin activity and a 
second wave of histamine activity. In human 
volunteers manifesting a cutaneous delayed-hyper-
sensitivity response, Goldyne et al [5] studied 
prostaglandin activity in sequential samples of 
saline perfusate taken from the involved skin. 
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Significant activity was detected coincident with 
the peak of clinical inflammatory changes, but 
activity could not be detected when clinical ery-
thema was first apparent (Fig. 4). These data 
indicate that, while prostaglandins may partici-
pate in inflammation, they do not appear to be the 
initial mediators. 
SOURCES OF CUTANEOUS PROSTAGLANDINS 
At least three sources may account for the 
prostaglandins that appear in cutaneous inflam-
mation. 
Skin. Jouvenaz, Nugteren, Beerthuis, and van 
Dorp [10] and van Dorp (11] recovered prosta-
glandins from rat whole-skin homogenates; upon 
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FIG . 3. Biosynthesis of prostaglandins E 2 and F 2" via 
endoperoxide intermediates-prostaglandins G2 and H2 (data from Samuelsson and Hamberg). 
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FIG. 2. Prostaglandins are named by letter according to substitutions on cyclopentane ring (top row). Letters with 
asterisks represent naturally occurring prostaglandins. A numerical subscript signifies degree of unsaturation of side 
chains (middle row). Greek letter signifies spatial orientation of substitutions on cyclopentane ring (bottom row). 
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TABLE I. Prostaglandins in human cutaneous 
inflammation 
Inflammatory stimulus 
Toxic 
Sunburn [2] 
Burn blisters [4] 
Cantharidin blisters [5] 
Benzalkonium chloride irritant dermatitis [6] 
Immunologic 
Contact dermatitis [5, 7) 
Pemphigus vulgaris0 
Bullous pemphigoida 
a Goldyne, Jordon, and Winkelmann: Unpublished 
data. 
separating the epidermis from the dermis, they 
found that the major portion of the activity was in 
the epidermis. Because rat skin placed in ethanol 
(to stop enzyme function) contained less activity 
than did rat skin placed in aqueous buffer, prosta-
glandins probably are not stored in the skin but 
rather are synthesized in response to the proper 
st imulus. In human epidermal homogenates, Jon-
sson and AnggArd [12] demonstrated the produc-
tion and metabolism of PGE 2 and PGF 2a utilizing 
tritiated arachidonic acid and thin-layer chroma-
tography. They found that arachidonic acid , the 
precursor of PGE 2 and PGF 2m is the major 20-car-
bon fatty acid esterified to skin phospholipids. 
Subsequently, Ziboh [13] found that the biosyn-
thetic capacity to produce prostaglandins resided 
in the microsomal fraction of human epidermal 
cells, thus showing that the prostaglandin synthe-
tase system was membrane-bound. Forstrom, Gal-
dyne, and Winkelmann [14] demonstrated that 
trypsinized human epidermal cells suspended in 
culture medium produced prostaglandins, as mea-
sured by radioimmunoassay. 
Leukocy tes. Higgs and Youlten [15] have re -
ported the production of PGE 1 by polymorphonu-
clear leukocytes of the rabbit during phagocytosis 
of bacteria . More recent ly, Ferraris and DeRuber-
tis [16] reported the release of PGE 2 by mitogen-
and antigen-stimulated leukocytes in culture. An-
derson , Brocklehurst, and Willis [17] and Di Rosa 
and Willoughby [18] found that prostaglandin 
activity in inflammation was correlated with the 
migration of leukocytes into the inflammatory 
focus. This observation could be explained by the 
release of prostaglandins from the invading cells. 
However, prostaglandin production by tissue cells 
(for example, the epidermal cells) in response to 
injury induced by the lysosomal enzymes released 
by neutrophils or macrophages can also explain 
these data. Phospholipase A, an enzyme capable of 
releasing free arachidonic acid substrate for prosta-
glandin synthesis, has been found in the neutrophil 
granules of the rabbit [19]. Subcutaneous injection 
of phospholipase A into rats has produced an 
exudate containing PGE 2-like activity [20]. 
Platelets. Studies by Smith and Willis [21], 
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Silver, Smith, Ingerman, and Kocsis [22], and 
Smith, Ingerman, Kocsis , and Silver [23] have 
shown that platelets released PGE 2 and PGF 2,. 
during clotting. Platelets also released an en-
doperoxide intermediate (possibly PGG or PGH), 
which may trigger the release of platelet contents. 
The activation of the clotting sequence during an 
inflammatory response could make available this 
source of prostaglandins. 
EFFECTS OF PROSTAGLANDINS ON VASCULAR AND 
CELLULAR COMPONENTS OF THE INFLAMMATORY 
RESPONSE 
Blood Vessels. Prostaglandins of the E group, as 
demonstrated by Solomon, Juhlin, and Kirschen-
baum [24], Juhlin and Michaelsson [25 ], and 
J~rgensen and S0ndergaard [26], caused whealing 
and erythema when injected into human skin . In 
rats , intradermal injection of PGE 1 or PGE 2 in-
creased cutaneous vascular permeabili ty [27]. A 
study by Crunkhorn and Willis [28] suggested that 
this response in rat skin was mediated by prosta-
glandin-induced histamine release , but Arora, La-
hiri , and Sanyal [29] did not find this association 
in their studies. In human subjects, the injection of 
antihistamine drugs failed to abolish the vascular 
response to PGE 1 • Using canine and human iso-
lated, cutaneous, vascular smooth muscle strips, 
Goldyne and Winkelmann [30] demonstrated that 
PGE 2 could exert a direct effect on cutaneous 
vessels. 
Prostaglandins of the F group, as demonstrated 
by Juhlin and Michaelsson [25 ], are far less active 
than those of the E group when injected into 
human skin. In the dog and rabbit, PGF2a caused 
vasoconstriction of the cutaneous vasculature [31 , 
32]. 
Leukocy tes. Kaley and Weiner [33] reported the 
in vitro chemotaxis of rabbit neutrophils toward a 
concentration of PGE 1• The degree of chemotaxis, 
however, was moderate and was only about 10% of 
that induced by activated serum . Diaz-Perez, 
Goldyne , and Winkelmann [34] were unable to 
demonstrate any in vitro chemotactic response to 
PGEt. E 2, F 10 , or F 2a by either rabbit or human 
neutrophils, even though these same cells re-
sponded well to known chemotactic agents such as 
casein . In addition, in vivo studies by Arora et al 
[29] failed to show any significant inflammatory 
infiltrate after a single intradermal injection of 
PGE 1 in rats. Multiple injections of PGE 1 into 
human skin were found by S~mdergaard, Helin, 
and Jprgensen [35] to produce a mononuclear cell 
infiltrate. McClatchey and Snyderman [36] found 
that PGE2, while not chemotactic in itself, en-
hanced the human mononuclear leukocyte re-
sponse to other chemotactic stimuli. S~ndergaard 
and Wolf-Jurgensen [37], using a skin window 
technique , demonstrated that the cellular se-
quence in response to PGE 1 did not differ from that 
of simultaneous control experiments. Thus, the 
direct chemotactic effect of E and F prostaglandins 
o~ leukocytes appears to be negligible. More recent 
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data, provided by Hill, Estensen, Goldberg, Ho-
gan, ·and Quie [38], suggest that PGE inhibits and 
PGF enhances the response of human neutrophils 
to other chemotactic agents. 
In regard to other leukocyte responses associated 
with inflammation, the E prostaglandins have 
been observed to exert a suppressive effect in vitro. 
Weissmann, Zurier, Spieler, and Goldstein [39], 
Weissmann, Dukor, and Zurier [40], Zurier and 
Weissman (41], and Zurier, Weissmann, Hoffstein, 
Kammerman, and Tai [42] demonstrated that 
PGEI could inhibit lysosomal enzyme release from 
human leukocytes exposed to immune complexes 
and other particles. This inhibition was also ob-
served by lgnarro, Oronsky, and Perper [43], who 
used isolated lysosome fractions from rat pancreas, 
spleen, and kidney cortex. Lichtenstein and Hen-
ney [44] and Bourne, Lichtenstein, and Melmon 
[45] found that both PGE 1 and PGE 2 inhibited the 
immunoglobulin E (lgE)-dependent, antigenically 
induced release of histamine from human leuko-
cytes (basophils). The former investigators also 
found that PGE 1 and PGE 2 inhibited the cytolytic 
activity of sensitized allogenic mouse lymphocytes 
against mastocytoma cells of the mouse [44 ]. 
Sm~th, Steiner, and Parker [46] reported that 
PGE 1 and PGE 2 prevented the transformation of 
human lymphocytes after exposure to the non-
specific mitogen, phytohemagglutinin. Bray, Gor-
don, and Morley [47] have observed the inhibition 
by PGE 1 of lymphokine secretion by sensitized hu-
man or guinea-pig lymphocytes in response to 
purified protein derivitive (PPD). Bryant and 
Sutcliffe [48] have reported the reduction of granu-
locyte adhesion by PGE 1 • Melmon, Weinstein, 
Shearer, and Bourne [49] found that PGE 1 and 
PGE 2 could suppress 198 antibody production 
by mouse lymphocytes sensitized to sheep red 
blood cells. 
Cellular responses to the F prostaglandins are 
June 1975 
more equivocal. In vitro. Weiner and Kaley [50] 
noted that PGF 2u, at a concentration of approxi-
mately l0- 5 M, caused lysosomal fragility. lgnarro 
et al [43] observed that PGF 2a had an apparent 
biphasic effect on lysosomal enzyme release, with 
low concentrations (lO- 7 M) inhibiting release and 
higher concentrations (lO- 6 to 10- 5 M) enhancing 
release. Zurier and Weissman [41], using only 
higher concentrations (10- 4 M), found that the 
PGF 20-associated lysosomal enzyme release from 
human leukocytes was associated with the induc-
tion· of cell injury. IgE-dependent histamine re-
lease and lymphocyte transformation, however, 
did not appear to be significantly affected by the F 
prostaglandins [ 44]. 
Collagen biosynthesis . Blumenkrantz and S~n­
dergaard [51] studied the effects of PGE 1 and 
PGF 10 on the hydroxylation of proline and lysine 
and on the glycosylation of hydroxylysine in the 
tibiae of the chick embryo. These prostaglandins 
increased the rate of both reactions, which are 
recognized biochemical markers of collagen bio-
synthesis. S~ndergaard et al [35] reported an 
increase of hyaluronic acid in human skin after an 
injection of PGE 1 • These data suggest that certain 
prostaglandins may initiate regenerative processes 
during cutaneous inflammation. 
PROSTAGLANDINS AND THE CYCLIC NUCLEOTIDES 
During the last 4 years, a large series of studies 
have demonstrated an intimate assoCiation be-
tween the effect (or hick of effect) of prostaglandins 
E and F on various cellular responses and their 
ability to elevate the concentration of cyclic adeno-
sine monophosphate (cAMP) within the respond-
ing target cell. Sutherland, Butcher, Robinson, et 
aJ [52-56] observed that cAMP was an intracellu-
lar second-messenger" responsible for evoking the 
characteristic response of a particular target tissue 
to a given extracellular hormone (first-messenger ). 
In 1970, Scott [57] reported that PGE 1 but not 
PGF t a could stimulate the production of cAMP in 
membrane fragments from human leukocytes, and 
subsequent studies by Stossel, Murad, Mason, and 
Vaughan [58], Zurier and Weissman [41 ], and 
Weissman et al [39,40] confirmed his findings in 
the intact cell and in addition suggested that PGE 1 
inhibited the in vitro release of lysosomal enzymes 
from human neutrophils through its ability to 
stimulate the production of cAMP within the 
neutrophil. The prostaglandin E-induced elevation 
of cAMP also appears responsible for the in vitro 
inhibition of lgE-mediated histamine release from 
basophils [44,45 ], for the suppression of leukocyte 
chemotactic response [38,59,60], and for the inhi-
bition of lymphocyte transformation [46] and 
lymphocyte-media ted cytotoxicity [ 44]. 
The inability of the F prostaglandins to signifi-
cantly elevate the concentration of intracellular 
cAMP appeared to explain the failure of this group 
of prostaglandins to suppress some of the afore-
mentioned leukocyte responses. However, this lack 
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of interaction did not explain the ability of the F 
prostaglandins to cause (unlike theE prostagland-
ins) vasoconstriction or enhancement of chemo-
taxis. 
Within the last 2 years, Goldberg, Haddox, 
Hartle , and Haddon [61] and Hill et al [38], as well 
as other investigators [42,62,63], have provided 
evidence that another intracellular nucleot ide , cy-
clic guanosine monophosphate (cGMP), can, when 
its production is stimulated, oppose the cellular 
functions promoted by cAMP. Thus, cGMP in-
creased lysosomal enzyme release from human 
neutrophils and isolated rat liver lysosomes [62, 
63 ], enhanced mitogenic stimulation of lympho-
cytes [64] and lymphocyte-mediated cytotoxicity 
[65 ], and enhanced leukocyte chemotactic re-
sponses to chemotactic stimuli [66] . The control of 
cellular function via the opposing effects of cAMP 
and cGMP has been coined the "Yin Yang" 
concept by Goldberg et al [61 ], referring to the 
oriental idea of a dualism between two opposing 
forces. 
The Yin Yang concept appears to provide some 
biochemical insights into the different and often 
opposing effects of the E and F prostaglandins on a 
given cell type or a given tissue. The ability of 
PGF 2a to enhance the release of lysosomal enzymes 
from human leukocytes may be related to a capac-
ity to increase cGMP within the leukocytes. The 
enhancement of chemotaxis by PGF 2a may be ex-
plained on a similar basis [38 ]. Recently, Dunham, 
Haddox, and Goldberg [67] demonstrated that 
PGF 2a caused contraction of isolated bovine and 
canine vein strips and that this contraction was 
associated with an increase in the ratio of cGMP 
to cAMP within the vascular smooth muscle. 
Conversely, PGE 2 relaxed the vein strips and in-
creased the cAMP level. Thus, in some systems, 
the F prostaglandins relate to cGMP as the E 
prostaglandins relate to cAMP. A more detailed 
review of the relationships among prostaglandins, 
cyclic nucleotides, and cell function has been pub-
lished recently [68 ]. The established and the pos-
sible examples of the dualism between effects 
mediated by PG E and cAMP and those mediated 
by PG F and cG MP are shown in Table II. The ob-
servations that, in some in vitro cell systems, both 
E and F prostaglandins exert a similar influence do 
not detract from this concept since some cell sys-
tems may, by virtue of their inherent differentia-
TABLE II. Dualism between effects of PGF and PGE on 
vascular and cellular expressions of inflammation 
Venoconstriction 
Venodilation 
Lysosomal enzyme release 
Chemotaxis 
PGF-induced PGE-induced 
elevation of elevation of 
cyclic-GMP cyclic-AMP 
Yes 
No 
Enhanced a 
Enhanced 
No 
Yes 
Inhibited 
Inhibited 
a May be secondary to direct cell injury by PG F 2 a [ 41 ] . 
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tion and specialized function, possess surface 1 N D 0 MET HAC 1 N (dose-response cur v.e) 
receptors, which can bind both E and F prosta-
glandins but which are structurally linked to only 1 0 0 
one nucleotide cyclase system. Furthermore, the 
conditions of an in vitro system may produce mis-
leading or uniquely in vitro responses. Both 
quantitative and qualitative alterations in vascular 
and cellular responses to both prostaglandins and 
the cyclic nucleotides can be demonstrated by us-
ing pharmacologic rather than physiologic concen-
trations of these agents [43,69) or by adjusting the 
calcium concentration [30, 70] or otherwise chang-
ing the ionic environment [71 ]. Further investiga-
tions should clarify the in vitro and in vivo interre-
lationships between prostaglandins and the cyclic 
nucleotides. 
PROSTAGLANDINS AS EXTRACELLULAR 
MODULATORS OF CUTANEOUS 
INFLAMMATION 
The previous discussion suggests that the ap-
pearance of both the E and F prostaglandins in 
cutaneous inflammation represents counterparts of 
a localized extracellular messenger system, which 
may, by affecting the intracellular levels of either 
cAMP or cGMP or possibly by effects independent 
of the cyclic nucleotide system, enhance or inhibit 
the vascular and cellular expressions of cutaneous 
inflammation produced by other molecular media-
tors. Thus, prostaglandins appear to serve as 
modulators of the inflammatory response. The 
observations that prostaglandins usually appear 
subsequent to other mediators [9] , that they can 
enhance the physiologic effects of other mediators 
[72, 73], and that the ratio of PG E to PG F varies 
during the evolution of irritant-induced inflamma-
tion in the rat [74] support the modulator theory of 
prostaglandin function in cutaneous inflamma-
tion. The more recent demonstration of the exist-
ence of the biologically active prostaglandin en-
doperoxide intermediates suggests that there may 
be other components to this modulator system. 
PROSTAGLANDINS AND THERAPEUTIC APPROACHES 
TO CUTANEOUS INFLAMMATION 
Vane [7 5], Ferreira, Moncada, and Vane [76], 
and Smith and Willis [77] were the first to demon-
strate the inhibition of prostaglandin biosynthesis 
by nonsteroidal anti-inflammatory drugs such as 
aspirin and indomethacin. Vane postulated that 
this inhibition was the mechanism through which 
these drugs produce their anti-inflammatory ef-
fect. Greaves and McDonald-Gibson [78] and 
Forstrom et al [14] have demonstrated the inhibi-
tion of prostaglandin biosynthesis by both aspirin 
and indomethacin in epidermal homogenates as 
well as in intact epidermal cells (Fig. 5). Synder 
and Eaglstein [79] demonstrated that the delayed 
erythema produced by sunburn-this erythema is 
believed, but not proved, to be mediated mainly by 
PGE2-is suppressed by indomethacin. 
However, it may be incorrect to assume that the 
anti-inflammatory effects of aspirin or indometha-
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FIG. 5. Concentration-dependent inhibition by indo-
methacin of prostaglandin biosynthesis by trypsinized 
human epidermal cells incubated for 18 hr in tissue 
culture medium 199. (From Forstrom L, Goldyne ME, 
Winkelmann RK : Prostaglandin production by human 
epidermal cells in vitro: a model for studying pharma-
cologic inhibition of prostaglandin synthesis. Prosta-
glandins 8:107- ' · ~:: 1974. ) 
cin derive solely from their ability to inhibit 
prostaglandin biosynthesis. For example, Kuehl 
[68] has reported (data from some unpublished 
studies) that indomethacin is a potent inhibitor of 
phosphodiesterase, which is the enzyme responsi-
ble for the metabolic breakdown of cAMP. This 
inhibition could lead to an increase in intracellular 
cAMP levels which, as discussed in the section 
concerning the cyclic nucleotides, can inhibit 
many cellular responses associated with the propa-
gation of the inflammatory response. DiRosa [80] 
has reported the inhibition of in vivo leukocyte 
migration (principally mononuclear leukocytes) in 
rats by both aspirin and indomethacin. Opelz and 
Terasaki [81] have demonstrated that aspirin can 
suppress human lymphocyte transformation in 
vitro. In addition, Moncada et al (73] found that 
indomethacin suppressed the carrageenan-induced 
edema in rats as early as 1 hr after injection, a time 
prior to that at which prostaglandin activity is 
detected in this experimental model [8,9]. The 
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inability of these nonsteroidal anti-inflammatory 
drugs to inhibit various types of cutaneous inflam-
mation from which prostaglandins can be re-
covered suggests that other mediators are contrib-
uting significantly to the inflammatory response. 
Future studies, using biologically active prosta-
glandin analogs that are less susceptible to meta-
bolic degradation or pros,taglandin antagonists, 
which compete with the native prostaglandins for 
binding, may lead to the development of agents 
that can select the beneficial effects of prosta-
glandins or block their untoward effects. Much 
work remains to be done in this area. Several 
reviews covering the studies of nonsteroidal anti-
inflammatory drugs and specific prostaglandin 
antagonists recently have been published [82-84]. 
The author wishes to thank Dr. R. K. Winkelmann for 
his helpful suggestions in the preparation of this paper. 
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